Skip to main content

Table 2 Concentrations (U/ml) (median values (IQR)) of anti-CCP2 antibodies in pre-patients, matched controls and RA patients

From: Antibodies of IgG, IgA and IgM isotypes against cyclic citrullinated peptide precede the development of rheumatoid arthritis

  IgA-CCP2 IgG-CCP2 IgM-CCP2
Controls (n = 276)a 0.8 1.2 18.5
(IQR) (0.5 to 1.1) (0.8 to 2.1) (11.1 to 34.3)
Pre-patients (n = 71)b 1.1* 3.4 ** 21.6 *
(IQR) (0.6 to 2.1) (1.2 to 55.0) (10.1 to 55.3)
Patients (n = 53)c 1.8*** 14.0 *** 51.9***
(IQR) (0.9 to 6.8) (11.4 to 715.5) (29.8 to 127.0)
p value1 <0.001 <0.001 <0.001
  1. a Analysis of IgM; n = 263 controls b, Analysis of IgM; n = 68 pre-patient samples, cAnalysis of IgA; n = 54 and of IgG-CCP2; n = 59, * P < 0.05, ** P < 0.01, ***P < 0.001 pre-patients vs. controls or RA patients vs. controls,1P-values obtained from Kruskal-Wallis analysis comparing all three groups. Anti-CCP, anti-cyclic citrullinated peptide; IQR, inter quartile range; Ig, immunoglobulin.